company background image
VERV logo

Verve Therapeutics NasdaqGS:VERV Stock Report

Last Price

US$5.60

Market Cap

US$470.2m

7D

6.1%

1Y

-71.8%

Updated

13 Jun, 2024

Data

Company Financials +

Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$470.2m

VERV Stock Overview

A clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.

VERV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Verve Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verve Therapeutics
Historical stock prices
Current Share PriceUS$5.60
52 Week HighUS$21.42
52 Week LowUS$4.90
Beta1.86
1 Month Change-10.11%
3 Month Change-59.45%
1 Year Change-71.77%
3 Year Change-82.46%
5 Year Changen/a
Change since IPO-82.46%

Recent News & Updates

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Recent updates

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Shareholder Returns

VERVUS BiotechsUS Market
7D6.1%0.2%1.0%
1Y-71.8%8.4%21.8%

Return vs Industry: VERV underperformed the US Biotechs industry which returned 8.4% over the past year.

Return vs Market: VERV underperformed the US Market which returned 21.8% over the past year.

Price Volatility

Is VERV's price volatile compared to industry and market?
VERV volatility
VERV Average Weekly Movement11.9%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: VERV's share price has been volatile over the past 3 months.

Volatility Over Time: VERV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018255Sek Kathiresanwww.vervetx.com

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company’s lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.

Verve Therapeutics, Inc. Fundamentals Summary

How do Verve Therapeutics's earnings and revenue compare to its market cap?
VERV fundamental statistics
Market capUS$470.21m
Earnings (TTM)-US$196.83m
Revenue (TTM)US$16.05m

29.3x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VERV income statement (TTM)
RevenueUS$16.05m
Cost of RevenueUS$186.21m
Gross Profit-US$170.16m
Other ExpensesUS$26.67m
Earnings-US$196.83m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.34
Gross Margin-1,060.27%
Net Profit Margin-1,226.43%
Debt/Equity Ratio0%

How did VERV perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.